Stefanie Fluckiger-Mangual

top of page

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company is targeting CBP/p300 just stared phase 1 data at World Lung

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity. Coverage brought to you by

Company News

4 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company is targeting CBP/p300 just stared phase 1 data at World Lung

Follow BiotechTV

Sponsors

Sponsor Spotlight